**Product Specification Sheet**

**Product Name:** PS-341 (Bortezomib)

**Catalog Number:** C7734

### Technical information:

- **Chemical Formula:** C_{19}H_{25}BN_{4}O_{4}
- **CAS #:** 179324-69-7
- **Molecular Weight:** 384.24
- **Purity:** > 98%
- **Appearance:** Light Yellow Crystalline solid
- **Solubility:** Soluble in DMSO up to 100 mM
- **Chemical Name:** [(1R)-3-methyl-1-[(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl]amino]butyl]boronic acid
- **Storage:** Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.
- **Shelf Life:** In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.

### Handling:

- To make 10 mM stock solution, add 0.26mL of DMSO for each mg of PS-341 (Bortezomib).
- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

### Biological Activity:

Bortezomib is a first-in-class dipeptide boronic acid-based, water-soluble proteasome inhibitor. As a single agent, bortezomib was found to have consistent antitumor activity in both chemosensitive and chemoresistant multiple myeloma cells at an IC50 of 10-20 ng/mL. [1] Bortezomib overcomes the resistance to apoptosis in multiple myeloma cells that is induced by IL-6. [2] Additionally, bortezomib prevents TNF-a-induced, NF-kB-dependent upregulation of IL-6 and reduces cell adhesion; proliferation of remaining adherent multiple myeloma cells was also inhibited by bortezomib. [1]

In MM cell lines U266, IM-9, and Hs Sultan, bortezomib inhibited at IC50 concentrations of 3, 6, and 20 nM, respectively. [2] Cell growth of Dox40, MR20, and LR5 MM cells was completely inhibited by bortezomib at 100 nM IC50.

Bortezomib suppresses growth and induces apoptosis in Bcr/Abl-positive cells sensitive and resistant to IM. Interestingly, sequential combination of bortezomib followed by imatinib resulted in a synergistic pro-apoptotic effect in imatinib-resistant cells; simultaneous exposure of bortezomib and imatinib was antagonistic. [3]

### Reference:

1. Richardson et al., Cancer Control, 2003, 10(6), 361-369.


For Technical Support: [technical@cellagentech.com](mailto:technical@cellagentech.com)

*Chemicals are sold for research use only, not for clinical or diagnostic use.*